Impact of Genetic Targets on Prostate Cancer Therapy

被引：4

作者：

Sheikh, Hassan ^{[1
]}

Abdulghani, Junaid ^{[2
]}

Ali, Suhail ^{[3
]}

Sinha, Raghu ^{[4
]}

Lipton, Alan ^{[1
]}

机构：

[1] Penn State Univ, Milton S Hershey Med Ctr, Div Hematol Oncol, Hershey, PA 17033 USA

[2] Penn State Coll Med, Penn State Hershey Canc Inst, Penn State Hershey Med Ctr, Dept Med Hematol Oncol, Hershey, PA 17033 USA

[3] Lebanon VA Hosp, Lebanon, PA USA

[4] Penn State Hershey Canc Inst, Dept Biochem & Mol Biol, Hershey, PA 17033 USA

来源：

IMPACT OF GENETIC TARGETS ON CANCER THERAPY | 2013年 / 779卷

关键词：

Prostate cancer; PSA; Digital rectal examination; Ultrasound; MRI; Gleason score; Androgen deprivation; External beam irradiation; Pelvic nodal radiation; Gonadotropin releasing hormone; Androgen blockade; Testosterone; Docetaxel; Sipuleucel-T; Cabazitaxel; Abiraterone acetate; Hyperdiploidy; Androgen receptor; NCOA2; MYC; NCOR1; ETS; PTEN; Akt; TMPRSS2-ERG; TP53; 3p14; FOXP1; RYBP; SHQ1; SLC45A3:ERG; KLK2:ETV1; PHASE-II TRIAL; MITOXANTRONE PLUS PREDNISONE; CIRCULATING TUMOR-CELLS; GROWTH-FACTOR RECEPTOR; PLACEBO-CONTROLLED TRIAL; HUMAN ANDROGEN RECEPTOR; RANDOMIZED-TRIAL; ABIRATERONE ACETATE; ZOLEDRONIC ACID; SIPULEUCEL-T;

D O I：

10.1007/978-1-4614-6176-0_17

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Given the global incidence of prostate cancer and its sociological impact, it remains a challenging disease to clinicians and researchers alike. In the last few years several new drugs have been added to the armamentarium of prostate cancer therapy and offers survival bene fit to patients with prostate cancer. However, effective drugs are still needed that offer extended survival bene fit and alter the natural history of the disease. Recent efforts have focused on better understanding the underlying biology and genetic heterogeneity of the disease and identified novel targets that can be utilized for drug development and therapeutics in the future. In this review we present an overview of the genetic landscape of prostate cancer, novel targets in the prostate cancer therapy and the results of key clinical trials of these novel drugs.

引用

页码：359 / 383

页数：25

共 121 条

[1] Deregulated homeobox gene expression in cancer: Cause or consequence? [J].

Abate-Shen, C .

NATURE REVIEWS CANCER, 2002, 2 (10) :777-785

[2]

Adib RS, 1997, BRIT J UROL, V79, P235

[3] Androgen receptor action in hormone-dependent and recurrent prostate cancer [J].

Agoulnik, Irina U. ;

Weigel, Nancy L. .

JOURNAL OF CELLULAR BIOCHEMISTRY, 2006, 99 (02) :362-372

[4] Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy [J].

Agus, David B. ;

Sweeney, Christopher J. ;

Morris, Michael J. ;

Mendelson, David S. ;

McNeel, Douglas G. ;

Ahmann, Frederick R. ;

Wang, Jin ;

Derynck, Mika K. ;

Ng, Kimmie ;

Lyons, Benjamin ;

Allison, David E. ;

Kattan, Michael W. ;

Scher, Howard I. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (06) :675-681

[5] Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor [J].

Andersen, Raymond J. ;

Mawji, Nasrin R. ;

Wang, Jun ;

Wang, Gang ;

Haile, Simon ;

Myung, Jae-Kyung ;

Watt, Kate ;

Tam, Teresa ;

Yang, Yu Chi ;

Banuelos, Carmen A. ;

Williams, David E. ;

McEwan, Iain J. ;

Wang, Yuzhou ;

Sadar, Marianne D. .

CANCER CELL, 2010, 17 (06) :535-546

[6]

[Anonymous], 2012, J CLIN ONCOL S

[7]

[Anonymous], J CLIN ONCOL S5

[8] Dasatinib combined with docetaxel for castration-resistant prostate cancer [J].

Araujo, John C. ;

Mathew, Paul ;

Armstrong, Andrew J. ;

Braud, Edward L. ;

Posadas, Edwin ;

Lonberg, Mathew ;

Gallick, Gary E. ;

Trudel, Geralyn C. ;

Paliwal, Prashni ;

Agrawal, Shruti ;

Logothetis, Christopher J. .

CANCER, 2012, 118 (01) :63-71

[9] Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer [J].

Attar, Ricardo M. ;

Jure-Kunkel, Maria ;

Balog, Aaron ;

Cvijic, Mary Ellen ;

Dell-John, Janet ;

Rizzo, Cheryl A. ;

Schweizer, Liang ;

Spires, Thomas E. ;

Platero, J. Suso ;

Obermeier, Mary ;

Shan, Weifang ;

Salvati, Mark E. ;

Foster, William R. ;

Dinchuk, Joseph ;

Chen, Shen-Jue ;

Vite, Gregory ;

Kramer, Robert ;

Gottardis, Marco M. .

CANCER RESEARCH, 2009, 69 (16) :6522-6530

[10] Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven [J].

Attard, Gerhardt ;

Reid, Alison H. M. ;

Yap, Timothy A. ;

Raynaud, Florence ;

Dowsett, Mitch ;

Settatree, Sarah ;

Barrett, Mary ;

Parker, Christopher ;

Martins, Vanessa ;

Folkerd, Elizabeth ;

Clark, Jeremy ;

Cooper, Colin S. ;

Kaye, Stan B. ;

Dearnaley, David ;

Lee, Gloria ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4563-4571

← 1 2 3 4 5 6 7 8 9 10 →